LTS Lohmann Therapie-Systeme AG

What LTS Lohmann Therapie-Systeme AG does

LTS Lohmann Therapie-Systeme AG is a privately held German pharmaceutical Contract Development and Manufacturing Organization (CDMO) headquartered in Andernach, Germany, specializing in non-invasive drug delivery systems. Founded in 1986, the company operates across three continents with 1,000+ employees and serves pharmaceutical and biotech partners from formulation development through commercial manufacturing and lifecycle management.

The company's technology portfolio spans six delivery platforms: Transdermal Therapeutic Systems (TTS), Oral Thin Films (OTF), Micro Array Patches (MAP), Topical Patch Systems (TOPS), Nasal Drug Delivery (NDD), and the Sorrel On-Body Delivery System (OBDS) for large-volume and highly viscous biologic formulations. The Sorrel platform was acquired from Eitan Medical in 2023 and is now being positioned within a three-way ecosystem partnership with Datwyler and Stevanato Group for large-volume subcutaneous biologic delivery. Recent capability additions include US-based sterile manufacturing via the 2025 acquisition of Renaissance Lakewood and the 2026 launch of ophthalmic drug delivery services in preservative-free multidose formats.

LTS operates a B2B enterprise CDMO model with revenue generated through managed services contracts covering R&D, process development, scale-up, and commercial manufacturing, complemented by technology licensing and partnership arrangements. Pricing is quote-based and project-dependent. Customers are primarily pharmaceutical and biotech companies, with additional global health engagement through Bill & Melinda Gates Foundation grants supporting MAP contraceptive and thermostable mRNA vaccine development. The company markets to enterprise decision-makers through direct sales, content marketing, white papers, webcasts, and industry events.

Name

LTS Lohmann Therapie-Systeme AG

Legal name

LTS Lohmann Therapie-Systeme AG

Website

https://ltslohmann.de

Company type

Private

Founded year

1986

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

LTS Lohmann Therapie-Systeme AG is a German CDMO specializing in non-invasive drug delivery systems — transdermal patches, oral thin films, microneedle arrays, nasal sprays, topical patches, and wearable injectors — serving pharmaceutical and biotech partners from concept through commercial manufacturing across three continents.

Ownership category

akta.pro rank

Product category

Pharmaceutical CDMO / Drug Delivery Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH), Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Transdermal drug delivery
• Pharmaceutical CDMO services
• Oral thin films
• Microneedle array patches
• Wearable injection devices

Headquarters

HQ city

Andernach

HQ country

Germany

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure

Revenue model

1. CDMO Services: Contract development and manufacturing organization services providing pharmaceutical and biotech partners with drug delivery solutions from R&D through commercial manufacturing. Revenue generated through service contracts for formulation development, process development, and manufacturing.
2. Technology Licensing and Partnerships: Strategic partnerships and technology collaborations, such as the Sorrel wearable injection platform integration into partner ecosystems like the Datwyler-Stevanato ecosystem.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

LTS Lohmann Therapie-Systeme AG is a German pharmaceutical CDMO that develops and manufactures non-invasive drug delivery systems, including transdermal patches, oral thin films, microneedle array patches, topical patches, nasal sprays, and wearable on-body injectors. The company serves pharmaceutical and biotech partners with end-to-end services spanning formulation R&D, process development, scale-up, commercial manufacturing, and lifecycle management across six proprietary delivery platforms.

Product overview

LTS Lohmann Therapie-Systeme AG is a German pharmaceutical technology company offering integrated non-invasive drug delivery solutions as a CDMO (Contract Development and Manufacturing Organization). The portfolio spans six core technology platforms: Transdermal Therapeutic Systems (TTS), Oral Thin Films (OTF), Micro Array Patches (MAP), Topical Patch Systems (TOPS), Nasal Drug Delivery (NDD), and the acquired Sorrel On-Body Delivery System (OBDS). These technologies deliver oral, transdermal, and intradermal medications systemically or locally. Competencies include R&D, Process Development, Manufacturing, CDMO services, and Skin Lab capabilities. The company operates across three continents with over 1,000 employees, serving pharmaceutical partners from concept to market launch and lifecycle management.

Differentiator

Problem solved

Functional benefit

Brands

• Sorrel™: A next-generation on-body delivery system (OBDS) for large volume and highly viscous formulations, enabling patients to self-administer therapies at home. Platform acquired from Eitan Medical Ltd in 2023.

Products and services

• Transdermal Therapeutic Systems (TTS) Transdermal patches applied to the skin that deliver drugs systemically, currently utilized in multiple active substances, ensuring safe, reliable, precise, and convenient application for patients. Targeted at pharmaceutical and biotech partners.
• Oral Thin Films (OTF) Very thin polymer films taken orally that release active substances via the mucosa. Used in a wide range of applications, offering advantages for pharmaceutical partners and patients.
• Micro Array Patches (MAP) Microscopic dissolvable needles that penetrate into the uppermost dermal layer to release active substances. Delivers faster onset, enhanced compliance, and reduced total healthcare costs. Used for contraceptives, vaccines, and various therapeutics.
• Sorrel On-Body Delivery System (OBDS) Next-generation wearable injection device platform for large volume (up to 20mL) and highly viscous formulations. Enables patients to self-administer biologic therapies at home.
• Topical Patch Systems (TOPS) Flexible, ready-to-use platform designed to deliver a wide range of topical medicines with fast pain relief and maximum comfort.
• Nasal Drug Delivery (NDD) Patient-friendly nasal drug delivery pathway including nasal sprays and sterile dosage forms, supported by aseptic manufacturing capabilities acquired and expanded via Renaissance Lakewood.
• Ophthalmic Drug Delivery Solutions CDMO service for clinical manufacturing of sterile ophthalmic products in preservative-free multidose devices. Leverages existing aseptic manufacturing infrastructure for nasal sprays and vials, with plans for end-to-end services from formulation development through commercial manufacturing.
• CDMO Contract Development and Manufacturing Services Contract Development and Manufacturing Organization (CDMO) services covering R&D, formulation development, process development, scale-up, commercial manufacturing, and lifecycle management of non-invasive drug delivery systems across transdermal, oral thin film, microneedle, topical, nasal, wearable injection, and ophthalmic platforms for pharmaceutical and biotech partners globally.

Quantifiable outcome

• Microneedle patches offer six-month duration for long-acting contraception
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature6 records

Partnerships

Two partnerships are on record, tiered core.

• Datwyler and Stevanato GroupcoreStrategic or Co-development Partner · 8 April 2026Three-way collaboration combining Datwyler's NeoFlex plungers, Stevanato's EZ-fill large-volume cartridges, and LTS's Sorrel platform into a pre-verified ecosystem for large-volume subcutaneous drug delivery (up to 20mL). Enables patients to self-administer biologic therapies at home, addressing the growing demand for decentralized healthcare.
• Eitan Medical LtdcoreTechnology or Integration · 8 June 2023LTS completed acquisition of the Sorrel wearable injection device business from Eitan Medical Ltd, headquartered in Netanya, Israel. This strategic move expanded LTS's drug delivery portfolio into large molecules and biologics, supporting pharmaceutical partners and preparing for product launch.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Catalent (Novo Holdings): Global CDMO with deep capabilities in oral, injectable, and respiratory drug delivery, including softgel and inhaled formats. Directly comparable as a full-service contract development and manufacturing partner for pharmaceutical innovators, though significantly larger and more diversified than LTS.
• Kindeva Drug Delivery: Specialty CDMO with strong transdermal patch and inhalation capabilities (formerly 3M Drug Delivery Systems). Competes most directly with LTS in transdermal therapeutic systems and shares the same enterprise pharma customer base.
• West Pharmaceutical Services: Global leader in injectable drug delivery components, including elastomeric closures, syringe systems, and wearable on-body injectors. Directly comparable to LTS's Sorrel OBDS and large-volume subcutaneous biologics delivery strategy, with stronger scale and a public-company balance sheet.
• Noven Pharmaceuticals (Hisamitsu): Transdermal patch specialist owned by Hisamitsu, focused on transdermal drug delivery for CNS and other indications. One of the closest direct competitors to LTS in TTS manufacturing, particularly for generic and branded patch products.
• Corium (TurbuHALER successor; acquired by Gurnet Point/LTS-adjacent investors): U.S.-based transdermal drug delivery and oral thin film CDMO with a portfolio overlapping LTS's TTS and OTF platforms. Direct competitor for pharma partner contracts in patch and oral film development and manufacturing.
• Halo Pharma (a Sentry BioPharma company): CDMO specializing in oral solid, liquid, and topical dosage forms including sterile and non-sterile manufacturing. Comparable to LTS's NDD and TOPS offerings and competes for similar mid-market pharma outsourcing contracts.
• Adare Pharmaceuticals (now part of Laxai Life Sciences): CDMO with technology platforms in oral modified release, taste-masking, and pediatric formulations. Comparable as a specialty drug delivery CDMO serving pharma partners, with overlap in oral and oral thin film development.

Broad incumbents

• BD (Becton Dickinson) - Pharmaceutical Systems: Diversified medical device and drug delivery conglomerate offering prefillable syringes, wearable injectors, and biologics delivery systems. Overlaps with LTS in injectable and on-body delivery but operates across a much broader medical device portfolio.
• Lonza Group: World's largest CDMO spanning small molecules, biologics, and cell & gene therapy manufacturing. Competes with LTS for CDMO share across pharmaceutical customers and represents the scale ceiling that mid-sized specialists like LTS must differentiate against.

Others

• Stevanato Group: Drug containment and delivery solutions provider, including EZ-fill pre-sterilized cartridges used in large-volume subcutaneous delivery. Strategic partner to LTS via the Datwyler-Stevanato ecosystem for Sorrel OBDS, while also being a complementary supplier in the broader drug delivery value chain.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries2 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LTS Lohmann Therapie-Systeme AG